Novartis imports some 120 million packs of medicines into the UK each year.
Keystone
Swiss pharmaceuticals giant Novartis says a no-deal Brexit could hurt patients and that it is stockpiling medicines in the UK to help ensure continuity of supply.
This content was published on
1 minute
swissinfo.ch/jc
In a press release on Friday, it said that after the British parliament’s rejection of Prime Minister Theresa May’s Brexit deal, “the risk of UK exiting the EU without a deal is increased and this will be hugely impactful for patients, particularly around the supply and safety of medicines”.
And it called for the British government to take action on medicines.
“It is vital that Government makes minimising disruption to the medicines supply the highest priority as it prepares for a potential hard or disorderly Brexit and ensures cooperation over medicines regulation in this event.”
The pharma giant said it is prioritising measures to ensure that patients in the UK can access medicines produced by Novartis and its Sandoz and Alcon affiliates. It imports some 120 million packs of medicines to the UK from Europe each year, according to the press release.
Novartis also urged the National Health Service and pharmacists in the UK to heed advice not to stockpile medicines, “so supply can be managed centrally, minimising the risk of medicine shortages across the UK”.
Novartis, maker of neurological, immunology and cancer drugs, employs around 1,500 people in the UK.
More
More
Brexit worries to keep Theresa May away from Davos
This content was published on
UK Prime Minister Theresa May, citing domestic concerns, has followed her French and American counterparts by pulling out of this year’s WEF.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
Switzerland and Norway have signed a bilateral agreement for the future storage of carbon dioxide (CO2) under the North Sea.
Switzerland must better protect whistleblowers, says OECD
This content was published on
Switzerland must step up its anti-corruption efforts and provide better protection for whistleblowers while increasing fines for guilty firms, an OECD anti-bribery group says.
Art Basel 2025 registers numerous million-dollar sales on first day
This content was published on
Galleries at the prestigious Art Basel fair in Switzerland have registered numerous million-dollar sales on the first preview day on June 17.
Trust in Swiss news is rising, Reuters report shows
This content was published on
Trust in the news has increased in Switzerland, according to the Reuters Institute Digital News Report 2025. Almost half (46%) of adults who took part in a recent survey said they generally trusted Swiss news, up 5%.
Five Swiss diplomats leave Tehran as Israel-Iran war enters sixth day
This content was published on
Five Swiss diplomats left the Iranian capital with their families by land by their own means on Tuesday, a Swiss foreign ministry spokesperson has confirmed.
Ex-employee of Bank Pictet convicted of money laundering
This content was published on
The Geneva-based bank Pictet has been fined CHF2 million for shortcomings in its organisation which enabled a former asset manager to commit serious money laundering.
20 Minuten: last Swiss free daily to stop being printed
This content was published on
From the end of the year, there will no longer be a daily free newspaper in Switzerland: the TX Group is discontinuing the print version of "20 Minuten". Up to 80 full-time positions are to be cut in the editorial and publishing departments.
This content was published on
The Swiss population is in favour of compulsory military service and closer ties with NATO. These are the findings of the "Security 2025" study.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
This content was published on
Swiss drugmaker Novartis is exploring working with the global reinsurance industry to help bear the cost of new personalised therapies.
Too few pharma companies prioritise access to medicines
This content was published on
Novartis and Roche both get a boost in the 2018 ranking of progress in expanding access to medicines by the biggest pharmaceutical companies.
This content was published on
Sandoz Inc. and Pear Therapeutics announced that that an app to help treat opium addicts was approved in the United States.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.